Campath halts MS disability progression in Phase II trial
This article was originally published in Scrip
Genzyme and Bayer HealthCarehave announced positive final results from a head-to-head Phase II trial of their leukaemia drug Campath (alemtuzumab) versus Rebif (high-dose interferon beta-1a) in patients with early relapsing-remitting multiple sclerosis. The data showed that Campath improved patients' mean disability EDSS score, while the scores of those taking Rebif – a standard MS treatment, deteriorated. The findings were published in the October 23rd issue of the New England Journal of Medicine.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.